July 10, 2020 Chris Richardson

Mr. Richardson has spent his 30-year career taking medical device startup companies from the clinical trial phase through worldwide commercialization and into acquisition. Prior to joining Keystone Heart, Mr. Richardson was international president and CCO of Direct Flow Medical, a transcatheter aortic valve company, and general manager of Abbott Vascular Structural Heart, a global company focused on percutaneous mitral valve repair, which he joined through its acquisition of Evalve. Mr. Richardson has also held leadership positions at Boston Scientific’s Cardiac Rhythm Management business and GSC Management Development at Guidant, Heartport (acquired by Johnson & Johnson) and Devices for Vascular Intervention (acquired by Guidant).